跳至主要内容
临床试验/NCT03162185
NCT03162185Unknown4 期

The Effects of Serotonergic Challenge on Motor Learning and Neuroplasticity

Max Planck Institute for Human Cognitive and Brain Sciences1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
60
试验地点
1
主要终点
Pinch Force Task.

研究概览

简要总结

With this study, the investigators aim to test whether acute administration of selective serotonin reuptake inhibitors (SSRI) improves motor performance in a sequential motor learning task in comparison to placebo in healthy humans.

详细描述

Microdialysis findings in animal models provide evidence for a monoaminergic augmentation of motor function. However, this evidence is largely limited to noradrenaline and dopamine, with little evidence to support a similar effect for serotonin. What remains to be tested therefore, is whether acute serotonergic administration induces neural or behavioral changes during motor learning also. Using a sample of 60 female participants (with the possible inclusion of male participants at a later date), the investigators aim to test the effects of a serotonergic challenge on motor learning and plasticity in healthy participants.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

盲法说明

Double-blind

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • right-handed
  • has taken oral contraceptives (ovulation inhibitor) continuously for at least 3 months
  • has read and agreed to study parameters

排除标准

  • tattoos on head or neck
  • non-removable metal on or in body
  • alcohol abuse
  • is currently taking medication
  • smokes more than 3 cigarettes per day
  • positive drug test
  • pregnancy
  • plays an instrument professionally
  • plays videogames more than 2 hours per week
  • is a professional athlete
  • suffers from migraines
  • has taken part in another study, where motor learning skills and/or medication is a factor, in the last 3 months
  • heart rhythm disorders (long QT)
  • hypertension
  • calcium or magnesium deficiency
  • neurological disorders
  • chronic metabolic disorders
  • liver or kidney diseases
  • immunodeficiency
  • endocrine disorders
  • psychiatric disorders
  • injuries to the head and brain

研究组 & 干预措施

Control group

Placebo Comparator

Half of the participants ( n= 30) will receive the placebo.

干预措施: Placebo (Drug)

Interventional group

Experimental

Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.

干预措施: Escitalopram (Drug)

结局指标

主要结局

Pinch Force Task.

时间窗: 1 week

The primary outcome measure will be reaction time and accuracy of motor responses, as measured by the Pinch Force Task. This will be applied to both the experimental (SSRI) and control (Placebo) groups.

次要结局

未报告次要终点

研究者

发起方
Max Planck Institute for Human Cognitive and Brain Sciences
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验